Is PT-141 (Bremelanotide) Legal in Texas?

What Is PT-141 (Bremelanotide) and Why Does Its Legal Status Matter?

PT-141, sold under the brand name Vyleesi, is a melanocortin receptor agonist that acts centrally on MC3R and MC4R receptors to increase sexual desire. The FDA approved bremelanotide on June 21, 2019, making it only the second drug approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. [1] Because it is a prescription drug with a specific approved indication, every layer of legal access flows from that single fact.

How PT-141 Differs from Research-Chemical Peptides

Many peptides sold online occupy a regulatory gray area because they have never been FDA-approved and are marketed as "research chemicals." PT-141 is not in that gray area. The FDA's approval of Vyleesi means bremelanotide is classified as a prescription drug under 21 U.S.C. § 353(b), the same statute governing drugs like metformin or lisinopril. [2] Possessing or dispensing it without a prescription violates federal law, not merely state pharmacy rules.

Why Texas Residents Ask About Legality

The confusion arises largely from the peptide-compounding market. Compounding pharmacies began offering injectable bremelanotide at lower prices than branded Vyleesi, and telehealth clinics advertise it widely. Whether those compounded versions are lawful depends on federal compounding law, not Texas-specific statutes, and that answer is more nuanced than most marketing copy suggests.

Federal Legal Framework for Bremelanotide

Federal law governs whether bremelanotide can be prescribed, dispensed, and compounded anywhere in the United States, including Texas. State law adds a second layer but cannot override federal rules.

FDA Approval and Prescription-Only Status

The FDA approved Vyleesi (bremelanotide) injection 1.75 mg/0.3 mL under NDA 210557 on June 21, 2019. [1] As a prescription drug, it may only be dispensed "upon a valid prescription order of a practitioner licensed by law to administer such drug," per 21 U.S.C. § 353(b)(1). [2] There is no federal over-the-counter pathway for bremelanotide, and no pathway is currently under review with the FDA.

The prescribing information approved by the FDA lists HSDD in premenopausal women as the sole indication and carries a boxed warning regarding transient decreases in blood pressure and increases in heart rate. [3] These safety signals informed the FDA's decision to require a prescription rather than allow OTC access.

DEA Scheduling

Bremelanotide is not listed under any DEA schedule (I through V) under the Controlled Substances Act. [4] That means Texas physicians do not need a DEA-registered controlled substance prescription to order it, and pharmacies do not face Schedule II dispensing restrictions. The drug is, however, still an Rx-only product, meaning the absence of a DEA schedule does not make it freely purchasable.

Compounding Under 503A and 503B

This is where legality becomes genuinely complicated. Under the Drug Quality and Security Act of 2013 (DQSA), Section 503A pharmacies (traditional compounders filling patient-specific prescriptions) may compound drugs that are not "essentially a copy" of an FDA-approved product. [5] Because Vyleesi is FDA-approved, a 503A pharmacy compounding bremelanotide is, on its face, compounding an essentially-copy drug, which is prohibited unless the patient has a documented clinical difference need (e.g., removing an excipient the patient cannot tolerate).

The FDA maintains a "bulks list" of bulk drug substances 503A and 503B pharmacies may use. Bremelanotide is NOT currently on the FDA 503A or 503B bulk substance lists as a permitted bulk ingredient. [6] That means compounding pharmacies that make bremelanotide from raw bulk powder are operating outside the explicit FDA framework for bulk compounding, which carries legal and regulatory risk for the pharmacy. Patients who receive compounded bremelanotide may receive a product that is not subject to the same quality controls as Vyleesi.

The FDA's guidance on essentially-copy compounding states: "A compounded drug product is essentially a copy of a commercially available drug product if it has the same active pharmaceutical ingredient(s), route of administration, dosage form, and strength." [7] Vyleesi at 1.75 mg/0.3 mL subcutaneous injection fits that definition exactly.

Texas State Legal Framework

Texas does not have a separate state-level law that re-classifies bremelanotide or adds restrictions beyond federal requirements. Understanding the three Texas-specific bodies of law that apply helps clarify what is permitted.

Texas Pharmacy Act and the Texas State Board of Pharmacy

The Texas Pharmacy Act (Texas Occupations Code, Chapter 558) requires that all prescription drugs dispensed to Texas patients be dispensed pursuant to a valid prescription from a licensed prescriber. [8] The Texas State Board of Pharmacy (TSBP) enforces these rules and has authority over both brick-and-mortar and out-of-state pharmacies shipping to Texas residents. The TSBP follows federal compounding law; it does not create a separate compounding framework that would make federally-questionable compounded bremelanotide lawful in Texas.

Texas Medical Practice Act

The Texas Medical Practice Act (Texas Occupations Code, Chapter 151) governs physician prescribing. A Texas-licensed physician may prescribe any FDA-approved prescription drug for any indication, including off-label uses, provided the prescription is based on a legitimate medical evaluation and serves the patient's medical need. [9] Prescribing bremelanotide for HSDD is fully within this authority. Prescribing it for off-label uses (such as male sexual dysfunction, which some clinicians use it for) is also permitted under Texas law, though the FDA has not evaluated bremelanotide for that indication. [9]

Texas Telemedicine Law

Texas House Bill 1560 (2021) and the subsequent rules adopted by the Texas Medical Board permit physicians to prescribe new medications to new patients via synchronous telemedicine (audio-video) without a prior in-person visit, provided the standard of care is met. [10] This means Texas residents can legally receive a bremelanotide prescription from a telehealth provider without visiting a clinic in person, as long as the prescribing physician conducts a thorough evaluation through a live video consultation.

How to Legally Obtain PT-141 (Bremelanotide) in Texas

Getting bremelanotide legally in Texas requires a prescription from a licensed Texas physician or a physician licensed in another state who is lawfully practicing telemedicine into Texas. The steps below describe the standard lawful pathway.

Step 1: Establish a Prescriber-Patient Relationship

A physician must conduct a medical evaluation before prescribing. For HSDD, this typically includes review of symptom duration (the HSDD diagnosis requires distressing low desire for at least six months), [11] exclusion of contributing conditions (thyroid disorder, depression, relationship factors), and medication reconciliation to check for drugs that reduce desire (such as SSRIs or hormonal contraceptives).

The FDA-approved prescribing information for Vyleesi notes the drug is indicated specifically for premenopausal women. [3] Prescribing it for postmenopausal women or men is off-label, and the physician bears responsibility for documenting the clinical rationale under the Texas Medical Practice Act. [9]

Step 2: Receive a Valid Written Prescription

The prescription must comply with Texas Occupations Code requirements: prescriber name and DEA number (even though bremelanotide is not scheduled, DEA numbers confirm licensure), patient name, date, drug name, strength, quantity, and directions. [8] Electronic prescriptions are lawful in Texas for non-controlled substances.

Step 3: Choose a Licensed Dispensing Pharmacy

For branded Vyleesi, any Texas-licensed retail pharmacy or mail-order pharmacy can fill the prescription. Patients choosing compounded bremelanotide should confirm the pharmacy holds a valid TSBP license and, ideally, PCAB (Pharmacy Compounding Accreditation Board) accreditation. [12] Given the 503A essentially-copy concern discussed above, patients should ask the prescriber to document the clinical rationale for compounding (e.g., preservative sensitivity) to satisfy legal requirements.

Step 4: Understand Cost and Access Realities

Branded Vyleesi carries a list price above $800 per autoinjector. Most commercial insurance plans do not cover it, and Medicare and Medicaid do not cover drugs for sexual dysfunction. [13] Compounded bremelanotide is widely available from telehealth-affiliated pharmacies at $150 to $300 for a multi-dose supply, but as outlined above, the legal standing of bulk-compounded bremelanotide is contested at the federal level.

Clinical Evidence Supporting Bremelanotide

Legal access is only meaningful if the drug works. Two key Phase 3 trials, RECONNECT Studies A and B (combined N=1,247 premenopausal women with HSDD), provided the efficacy data the FDA used for approval. [14]

RECONNECT Trial Results

In RECONNECT, bremelanotide 1.75 mg subcutaneous self-injection demonstrated statistically significant improvements compared to placebo on two co-primary endpoints: the Female Sexual Function Index-desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score. [14] The mean increase in satisfying sexual events per month was 0.7 events greater than placebo (P<0.001). [14]

Nausea occurred in approximately 40% of bremelanotide-treated patients versus 1.3% of placebo patients. [3] Transient blood pressure decreases occurred within 12 hours of dosing in about 13% of patients. [3] These rates informed the FDA's recommendation to avoid use in patients with cardiovascular disease. [3]

Off-Label Use in Men

Some clinicians prescribe bremelanotide off-label for erectile dysfunction or low libido in men. A pilot study published in the Journal of Sexual Medicine (N=24 men with erectile dysfunction) found improvements in erectile function scores after intranasal bremelanotide, though this early formulation differed from the approved subcutaneous injection. [15] The current FDA-approved product has not been evaluated in controlled trials in men, and this off-label use carries the legal prescribing considerations noted above under the Texas Medical Practice Act. [9]

The Gray Area: Compounded PT-141 Sold Online

Several websites sell vials labeled "PT-141 research peptide" without requiring a prescription. These are federally illegal when sold for human use. The FDA has issued multiple warning letters to companies selling unapproved peptides for human consumption, citing violations of 21 U.S.C. § 331(d), which prohibits the introduction of unapproved new drugs into interstate commerce. [16]

What "Research Chemical" Labeling Actually Means

Labeling a drug "for research use only" or "not for human consumption" does not exempt a product from FDA oversight if it is intended for human use. The FDA's policy is that intended use, not labeling, determines regulatory status. [16] A Texas resident purchasing injectable bremelanotide from an online peptide vendor without a prescription is receiving an unapproved drug, regardless of the label. The FDA could take enforcement action against the seller; the buyer may also face scrutiny depending on quantity.

Texas-Specific Enforcement Risk

The Texas Department of State Health Services (DSHS) works with the FDA on drug enforcement actions. While individual possession of small quantities of unapproved drugs for personal use rarely leads to state prosecution, Texas Health and Safety Code Chapter 431 mirrors the federal Food, Drug, and Cosmetic Act and gives DSHS authority to act against unapproved drug distribution within the state. [17] No documented Texas prosecutions of individual patients for possessing research-labeled peptides were identified at the time of this article's review, but the legal exposure for vendors is real and documented.

Prescribing Decision Framework for Clinicians

Texas clinicians considering bremelanotide for a patient should work through the following checklist before issuing a prescription. This framework was developed by the HealthRX medical team based on the FDA prescribing information, [3] the Texas Medical Practice Act, [9] and TSBP compounding rules. [8]

Step 1. Confirm indication. Is the patient a premenopausal woman with HSDD (distressing low desire persisting at least 6 months, not explained by relationship factors, another medical condition, or a medication)? If yes, on-label prescribing applies. If no (male patient, postmenopausal woman, or different sexual dysfunction), document the off-label rationale explicitly in the chart.

Step 2. Screen for cardiovascular contraindications. The Vyleesi prescribing label contraindicates use in patients with known cardiovascular disease. [3] Obtain a blood pressure reading at the time of evaluation and document it.

Step 3. Review drug interactions. Bremelanotide slows gastric emptying and may reduce absorption of orally administered drugs taken around the time of dosing. [3] Review the medication list for narrow-therapeutic-index oral drugs.

Step 4. Decide branded vs. Compounded. Prescribe branded Vyleesi when cost is not prohibitive or insurance may cover it. If prescribing compounded bremelanotide, document the specific clinical rationale (e.g., excipient intolerance) to satisfy the 503A essentially-copy defense. Confirm the pharmacy holds TSBP licensure and ask for a certificate of analysis. [12]

Step 5. Document telehealth standard of care. If prescribing via telemedicine, note that the synchronous audio-video consultation met the standard required by Texas Medical Board rules adopted under HB 1560. [10]

What the Experts Say

The American Society for Reproductive Medicine (ASRM) and the International Society for the Study of Women's Sexual Health (ISSWSH) have both addressed bremelanotide in clinical guidance. ISSWSH's 2021 Process of Care consensus document states: "Bremelanotide is FDA-approved for HSDD in premenopausal women and should be considered when non-pharmacologic strategies are insufficient or when the patient prefers pharmacotherapy." [18]

The FDA's own approval announcement noted: "Vyleesi is the second FDA-approved treatment for HSDD in premenopausal women. Having multiple treatment options is important because individual responses to treatment can vary." [1]

Summary of Legal Pathways in Texas

| Pathway | Legal Status in Texas | Notes | |---|---|---| | Branded Vyleesi with valid Rx | Fully legal | Fill at any licensed pharmacy | | Compounded bremelanotide with Rx and documented clinical reason | Conditionally legal (gray area federally) | 503A essentially-copy concern applies | | Compounded bremelanotide with Rx, no documented clinical difference | Legally questionable federally | Pharmacy bears regulatory risk | | Research-chemical PT-141 without Rx | Illegal federally; enforceable under Texas HSC Ch. 431 | Unapproved new drug in interstate commerce | | Telehealth Rx after synchronous video visit | Fully legal under Texas HB 1560 | Must meet standard of care |